康柏西普不同给药方案治疗有临床意义的糖尿病性黄斑水肿疗效比较  

Therapeutic effects of different dosage regimens of Conbercept on clinical significant diabetic macular edema

作　　者：李彬彬[1] 谭美华[1] 殷章亮 Bin-Bin Li;Mei-Hua Tan;Zhang-Liang Yin(Department of Ophthalmology, Ganzhou People's Hospital, Ganzhou 341000, Jiangxi Province, China)

机构地区：[1]中国江西省赣州市人民医院眼科,341000

出　　处：《国际眼科杂志》2022年第1期130-134,共5页International Eye Science

摘　　要：目的:观察康柏西普不同给药方案治疗有临床意义的糖尿病性黄斑水肿(CSME)的疗效。方法:选取2019-01/2020-01赣州市人民医院眼科收治的糖尿病伴有CSME患者65例为研究对象,采用随机数字表法将其分为观察组(33例,采用康柏西普5+PRN方案治疗)、对照组(32例,康柏西普3+PRN方案治疗),治疗后1、2、3、6、9、12mo进行视力、光相干断层扫描(OCT)检查,对比两组治疗前后最佳矫正视力(BCVA,LogMAR)、黄斑中心视网膜厚度(CMT)变化,记录两组平均注射次数、并发症发生情况。结果:两组治疗后1、2、3、6、9、12mo BCVA均较治疗前改善,CMT变薄(P<0.05),两组间治疗前、治疗后1、2、3、6、9、12mo BCVA、CMT比较均无差异(P>0.05);观察组平均注射次数5.81±0.54次,较对照组4.19±0.41次多(P<0.05);术后随访早期,观察组、对照组分别出现结膜下出血30次(23%)、15次(22%),无差异(P>0.05),两组均未见其他严重并发症。结论:康柏西普3+PRN或5+PRN方案治疗糖尿病伴CSME均有较好疗效,可提高视力,降低CMT,两种方案的改善效果相当,5+PRN方案可能增加注射次数,但不良反应可耐受,安全可靠。AIM:To observe the therapeutic effects of different dosage regimens of conbercept on clinical significant diabetic macular edema(CSME).METHODS:Totally 65 patients with diabetes and CSME who were admitted to the Ophthalmology Department at Ganzhou People’s Hospital between January 2019 and January 2020 were selected as the research subjects,and divided into observation group(n=33,conbercept 5+PRN regimen)and control group(n=32,conbercept 3+PRN regimen)using random number table method.Visual acuity test and optical coherence tomography(OCT)were carried out at 1,2,3,6,9,12mo after treatment.Changes in the best corrected visual acuity(BCVA,LogMAR)and central macular thickness(CMT)were compared between the two groups.The mean injection times and complications in the two groups were recorded.RESULTS:The BCVA was improved and CMT thinned in the two groups at 1,2,3,6,9,12mo after treatment(P<0.05).There was no statistically significant difference in BCVA and CMT between the two groups before treatment,and at 1,2,3,6,9,12mo after treatment(P>0.05).The mean injection times in observation group was more than that in the control group[(5.81±0.54)times vs(4.19±0.41)times](P<0.05).In the early stage of postoperative follow-up,there were 30 times(23%)and 15 times(22%)of subconjunctival hemorrhage in observation group and control group,respectively(P>0.05).No other severe complications were observed in the two groups.CONCLUSION:Both conbercept 3+PRN and conbercept 5+PRN are effective in the treatment of patients with diabetes and CSME.Both can significantly improve the patients’visual acuity and reduce CMT,with equivalent effect.The latter may increase the injection times but its adverse reactions are tolerable.In addition,it is safe and reliable.

关 键 词：康柏西普 给药方案 糖尿病 有临床意义的糖尿病性黄斑水肿 

分 类 号：R587.2[医药卫生—内分泌] R774.5[医药卫生—内科学]